Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya

This publication has 12 references indexed in Scilit:

• A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques
  Journal of General Virology, 2002
• Prospect of a prophylactic vaccine for HIV
  British Medical Bulletin, 2001
• Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.
  Nature Medicine, 2000
• Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen
  The Journal of Immunology, 2000
• Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids
  Nucleic Acids Research, 1998
• Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
  Vaccine, 1998
• Potential DNA Vaccine Integration into Host Cell Genome
  Annals of the New York Academy of Sciences, 1995
• Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen
  Journal of General Virology, 1992
• An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.
  Proceedings of the National Academy of Sciences, 1988
• Passage history, properties and applicability of the attenuated vaccinia virus strain MVA
  Infection, 1975